A Study of MT-0551 in Patients With Systemic Sclerosis

NCT05198557 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Sclerosis

Interventions

DRUG: Inebilizumab
DRUG: Placebo

Sponsor

Tanabe Pharma Corporation